Difficulty: Medium
Average Score: 81%
Practice
The mechanism of carbidopaÔÇ▓s action is:
Correct answer
B
Rationale
In the context of lifespan pharmacology, understanding the mechanism of action of carbidopa is crucial for healthcare professionals. Carbidopa is a medication commonly used in conjunction with levodopa to treat Parkinson's disease. The correct answer, option B, "Inhibition of dopa decarboxylase," is the mechanism of carbidopa's action.
Carbidopa works by inhibiting the enzyme dopa decarboxylase in the peripheral tissues. This enzyme normally converts levodopa into dopamine outside of the central nervous system, leading to side effects like nausea and cardiovascular effects. By inhibiting dopa decarboxylase, carbidopa allows more levodopa to reach the brain and be converted into dopamine centrally, where it is needed to alleviate Parkinson's symptoms.
Option A, "Stimulating the synthesis, release, or reuptake of dopamine," is incorrect because carbidopa does not directly impact dopamine synthesis, release, or reuptake. Option C, "Stimulating dopamine receptors," is also incorrect as carbidopa does not directly act on dopamine receptors. Option D, "Selective inhibition of catechol-O-methyltransferase," is incorrect as this describes the mechanism of action of another medication, entacapone, used in Parkinson's disease treatment but not carbidopa.
Understanding the mechanism of carbidopa's action is essential for healthcare professionals to optimize treatment for patients with Parkinson's disease and minimize side effects. By inhibiting dopa decarboxylase, carbidopa enhances the effectiveness of levodopa therapy, improving symptom control and quality of life for patients.
Carbidopa works by inhibiting the enzyme dopa decarboxylase in the peripheral tissues. This enzyme normally converts levodopa into dopamine outside of the central nervous system, leading to side effects like nausea and cardiovascular effects. By inhibiting dopa decarboxylase, carbidopa allows more levodopa to reach the brain and be converted into dopamine centrally, where it is needed to alleviate Parkinson's symptoms.
Option A, "Stimulating the synthesis, release, or reuptake of dopamine," is incorrect because carbidopa does not directly impact dopamine synthesis, release, or reuptake. Option C, "Stimulating dopamine receptors," is also incorrect as carbidopa does not directly act on dopamine receptors. Option D, "Selective inhibition of catechol-O-methyltransferase," is incorrect as this describes the mechanism of action of another medication, entacapone, used in Parkinson's disease treatment but not carbidopa.
Understanding the mechanism of carbidopa's action is essential for healthcare professionals to optimize treatment for patients with Parkinson's disease and minimize side effects. By inhibiting dopa decarboxylase, carbidopa enhances the effectiveness of levodopa therapy, improving symptom control and quality of life for patients.